J&J Rx drug sales flat, consumer and devices up

Share this article:
Johnson & Johnson flaunted the benefits of its diversified and global business portfolio today, reporting respectable third-quarter results despite static worldwide pharmaceutical sales of $6.1 billion.

Overall sales were up 6.4% for the quarter, year-on-year, to $15.9 billion. But with the company's prescription drugs business hit by generic competition and overall US sales flat, the growth came from J&J's consumer products and medical device and diagnostics businesses, along with healthy international sales.

Schizophrenia drug Risperdal, in particular, lost US patent protection in June and saw sales slide 62% year-on-year. Long-acting injectable Risperdal Consta, which remains on-patent, saw a 10% jump in sales. Other strong performers among the company's portfolio of prescription drugs included Velcade for multiple myeloma; Remicade for Chron's, rheumatoid arthritis and psoriasis; and Topamax for epilepsy and migranes.

Worldwide consumer sales were up 13.1% to $4.1 billion on a successful US launch of OTC Zyrtec and strong sales of Listerine, Neutrogena, Clean & Clear and Aveeno, as well as international baby care products and Davao, the leading moisturizer in China.

Medical devices and diagnostics sales were up 8.8% for the quarter to $5.7 billion, buoyed by strong performances by J&J Diabetes Care's blood glucose monitoring and insulin delivery products; Ethicon Endo-Surgery's minimally invasive products, Vistakon's disposable contact lenses; Ortho-Clinical Diagnostics' professional products and DePuy's orthopaedic joint reconstruction, sports medicine and trauma businesses. However, Cordis sales were hit by new competition and continuing category-wide safety fears in the drug-eluting stent market.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.